Communiqués Sagimet Biosciences Inc.

Actions

SGMT

US7867001049

Cours en clôture Nasdaq Autres places de cotation 00:00:00 28/05/2024			Varia. 5j.	Varia. 1 janv.
5,17 ^USD	+7,26%		+7,26%	-4,61%

16/05	SAGIMET BIOSCIENCES INC. : Goldman Sachs reste à l'achat	ZM
15/05	Sagimet Biosciences Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2024	CI

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 23, 2024	16/05	GL
Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 23, 2024	16/05	AQ
Sagimet Biosciences Reports First Quarter 2024 Financial Results and Provides Corporate Updates	15/05	GL
Sagimet Biosciences Reports First Quarter 2024 Financial Results and Provides Corporate Updates	15/05	AQ
Sagimet Announces Oral Presentation of Data from the Phase 2b FASCINATE-2 Study of Denifanstat in MASH at EASL International Liver Congress 2024	07/05	GL
Sagimet Biosciences Announces Appointment of Thierry Chauche as Chief Financial Officer	06/05	GL
Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 3, 2024	22/04	GL
Sagimet Biosciences Announces Completion of Phase 1 Hepatic Impairment Study with FASN Inhibitor Denifanstat	27/03	GL
Sagimet Biosciences Announces Completion of Phase 1 Hepatic Impairment Study with FASN Inhibitor Denifanstat	27/03	AQ
Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors	25/03	GL
Sagimet Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates	25/03	GL
Sagimet Biosciences to Participate in Two Upcoming Investor Conferences	29/02	GL
Sagimet Biosciences to Participate in Two Upcoming Investor Conferences	29/02	AQ
Sagimet Biosciences Announces Pricing of Public Offering of Series A Common Stock	26/01	GL
Sagimet Biosciences Announces Proposed Public Offering of Series A Common Stock	23/01	GL
Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASH	22/01	GL
Sagimet Biosciences to Participate in the First Annual Goldman Sachs Catalyst Clinic	04/12	GL
Sagimet Biosciences to Participate in the First Annual Goldman Sachs Catalyst Clinic	04/12	AQ
Sagimet Biosciences Announces Oral Presentation of Preclinical Results of FASN Inhibitor in Combination with Semaglutide at the 7th Obesity and NASH Drug Development Summit	28/11	GL
Sagimet Biosciences Announces Oral Presentation of Preclinical Results of FASN Inhibitor in Combination with Semaglutide at the 7th Obesity and NASH Drug Development Summit	28/11	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Sagimet Biosciences Inc.

Actions

SGMT

US7867001049

Communiqués

Filtres